NRx Pharmaceuticals (NASDAQ:NRXP) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report issued on Tuesday,Benzinga reports. They currently have a $31.00 price target on the stock.

NRXP has been the subject of a number of other research reports. Ascendiant Capital Markets lifted their target price on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price on shares of NRx Pharmaceuticals in a research report on Monday, November 25th. Finally, EF Hutton Acquisition Co. I raised shares of NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st.

NRx Pharmaceuticals Trading Up 35.9 %

Shares of NRx Pharmaceuticals stock opened at $2.99 on Tuesday. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $7.33. The stock has a 50 day moving average of $1.35 and a 200 day moving average of $1.76. The firm has a market cap of $36.16 million, a PE ratio of -1.40 and a beta of 1.25.

Insider Activity

In other news, Chairman Jonathan C. Javitt acquired 40,000 shares of the stock in a transaction that occurred on Tuesday, December 17th. The shares were bought at an average cost of $1.17 per share, for a total transaction of $46,800.00. Following the acquisition, the chairman now owns 84,634 shares in the company, valued at approximately $99,021.78. This represents a 89.62 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 19.00% of the company’s stock.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP bought a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned approximately 1.33% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.